New perspectives in the management of non-small cell lung cancer (NSCLC) Gefitinib (Iressa, ZD 1839)

European Journal of Cancer, Supplement

Volumn 2, Issue 4, 2004, Pages 34-39

  Manegold, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE;

ACNE; ALOPECIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NAUSEA; NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS SYNDROME; REVIEW; SIDE EFFECT; SKIN DISEASE; VOMITING;

EID: 2442419224     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2003.11.002     Document Type: Article

References (24)

1. Negoro S., Nakagawa K., Fukuoka M., et al. Final results of a phase I intermittent dose-escalation trial of ZD 1839 (Iresssa) in Japanese patients with various solid tumors. Proc. Am. Soc. Clin. Oncol. 20:2001;324. (abstr 1292)
2. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20:2002;4292-4302
3. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor - tyrosine kinase inhibitor ZD 1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors results of a phase I trial. J. Clin. Oncol. 20:2002;3815-3825
4. Ranson M., Hammond L.A., Ferry D., et al. ZD 1839, a selective oral epidermal growth factor receptor - tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors results of a phase I trial. J. Clin. Oncol. 20:2002;2240-2250
5. Miller V.A., Johnson D.H., Krug L.M., et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib plus Carboplatin and Paclitaxel in patients with stage IIIB or IV non-small cell lung cancer. J. Clin. Oncol. 21:2003;2094-2100
6. Gonzalez-Larriba J., Giaccone G., van Oosterom A.T., et al. ZD 1839 (Iressa) in combination with Gemcitabine and Cisplatin in chemo-naive patients with advanced solid tumors final results of a phase I trial. Proc. Am. Soc. Clin. Oncol. 21:2002;95a. (abstr 376)
7. Kris M., Natale R.B., Herbst R.S., et al. Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer a randomized trial. JAMA. 290:2003;2149-2158
8. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 21:2003;2237-2246
9. Shah N.T., Miller V.A., Kris M.G., et al. Bronchiolo-alveolar histology and smoking history predict response to Gefitinib (Iressa). Proc. Am. Soc. Clin. Oncol. 22:2003;. (abstr. 2524)
10. Cella D.F., Bonomi A.E., Lloyd R.S.R., et al. Realibility and validity of the functional assessment of cancer therapy-lung (Fact-L) quality of life instrument. Lung Cancer. 12:1995;199-220
11. Cella D.F., Tulsky D.S., Gray G., et al. The functional assessment of cancer therapy scale development and validation of the general measure. J. Clin. Oncol. 11:1993;570-579
12. Giaccone G., Johnson D.H., Manegold C., et al. A phase III clinical trial of ZD 1839 (IRESSA) in combination with Gemcitabine and Cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann. Oncol. 13:(Suppl. 5):2002;2. (abstr 4)
13. Johnson D.H., Herbst R., Giaccone G., et al. ZD 1839 (IRESSA) in combination with Paclitaxel and Carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer results from a phase III clinical trial (INTACT 2). Ann. Oncol. 13:(Suppl. 5):2002;127. (abstr 468)
14. Giaccone G., Johnson D., Scagliotti G.V., et al. Results of a multivariat analysis of prognostic factors of overall survival of patients with advanced non-small cell lung cancer treated with Gefitinib (ZD 1839) in combination with platinum-based chemotherapy in two large phase III trials (INTACT 1 and 2). Proc. Am. Soc. Clin. Oncol. 22:2003;627. (abstr 2522)
15. Herbst R.S., Giaccone G., Schiller J., et al. Subset analysis of INTACT results for Gefitinib (ZD 1839) when combined with platinum-based chemotherapy for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;672. (abstr 2523)
16. Kanemura T., Suzuki H., Aoshiba K., et al. Acute lung injure in lung cancer patients treated with ZD 1839 and Pleomycin-induced pulmonary fibrosis in mice. Proc. Am. Soc. Clin. Oncol. 22:2003;652. (abstr 2624)
17. Tamura K, Yamamoto N, Takeda K, et al. An epidemiological survey for interstitial lung disease induced by Gefitinib in patients with advanced non-small cell lung cancer. West Japan.
18. Snimizkawa M., Ebina M., Inoue A., et al. Acute onset of interstitial pneumonia in patients with non-small cell lung cancer treated with Gefitinib. Am. J. Resp. Great. Car. Med. 167:(Suppl. 7):2003;405. (abstr 993)
19. Kinoshita A., Fukuda M., Nagashima S., et al. Pulmonary damage during Gefitib monotherapy in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;698. (abstr 2809)
20. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and Gefitinib. The Lanced. 361:2003;137-139
21. Okamoto I., Fujii K., Matsumoto M., et al. Diffuse alveolar damage after ZD 1839 therapy in a patient with non-small cell lung cancer. Lung Cancer. 40:2003;339-342
22. Fandi A., Gatzemeier U., Smith R., et al. Final data from a pilot trial of Gefitinib (ZD 1839) in combination with Docetaxel in patients with advanced or metastatic non-small cell lung cancer safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol. 22:2003;655. (abstr 2635)
23. Gumerlock P.H., Pryde B.J., Kimura T., et al. Enhanced cytotoxicity of Docetaxel and OSI-774 combination in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;662. (abstr 2661)
24. Tada H., Tsuboi M., Mistudomi T., et al. Adjuvant therapy for Gefitinib (IRESSA, ZD 1839) following complete resection in Japanese patients with non-small cell lung cancer safety report of the first 38 patients recruited. Eur. J. Cancer. 1:(Suppl. 5):2003;243. (abstr 811)